Cochrane · systematic review · CD011230
Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration
Moja, L, Lucenteforte, E, Kwag, KH, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 6 · 85.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: patients with neovascular age‐related macular degeneration
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause death | RR 1.1 [0.78, 1.57] | 8 studies · 3338 participants | Moderate Downgraded: risk of bias |
All serious systemic adverse events | RR 1.08 [0.9, 1.31] | 9 studies · 3665 participants | Low Downgraded: risk of bias |
Infection | RR 1.34 [0.97, 1.86] | 6 studies · 3190 participants | Moderate Downgraded: risk of bias |
Arterial thromboembolic event | RR 0.92 [0.62, 1.37] | 6 studies · 3190 participants | Moderate Downgraded: risk of bias |
Myocardial infarction | RR 0.84 [0.42, 1.66] | 6 studies · 3190 participants | Moderate Downgraded: risk of bias |
Stroke | RR 0.83 [0.42, 1.66] | 6 studies · 3190 participants | Moderate Downgraded: risk of bias |
Gastrointestinal disorders MedDRA class | RR 1.82 [1.04, 3.19] | 6 studies · 3190 participants | Moderate Downgraded: risk of bias |